Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Prostate Cancer

Free Subscription Articles published in BJU Int Retrieve available abstracts of 240 articles: HTML format

Single Articles

July 2026
1. 
   Focus on the management of prostate cancer.
   BJU Int. 2026;138:6-7.
   PubMed    
   
   
   June 2026
2. CHENG HH, Maxwell KN, Salari K, Cooperberg MR, et al
   The 'Prostate Cancer Screening for People at Genetic Risk of Aggressive Disease' (PATROL) study.
   BJU Int. 2026 Jun 9. doi: 10.1111/bju.70334.
   PubMed     Abstract available
   
   
   
3. BOSHARI T, Anderson A, Richards M
   More harm than good? The UK National Screening Committee's latest review of prostate cancer screening.
   BJU Int. 2026 Jun 8. doi: 10.1111/bju.70355.
   PubMed     Abstract available
   
   
   
4. CALPIN GG, Hehir CM, Alzayer M, MacCurtain BM, et al
   Transrectal vs transperineal prostate biopsy: a systematic review and meta-analysis.
   BJU Int. 2026;137:958-967.
   PubMed     Abstract available
   
   
   May 2026
5. LU S, Roque C, Saranchuk J, Ahmad AE, et al
   Active surveillance for intermediate risk prostate cancer: the Manitoba Prostate Center experience.
   BJU Int. 2026 May 20. doi: 10.1111/bju.70318.
   PubMed     Abstract available
   
   
   
6. MESZES-TOTH A, Gyulai AT, Izsak B, Erdelyi AE, et al
   Preliminary results and experiences of fluorescence confocal microscopy using the Histolog(R) Scanner in prostate cancer diagnostics: a feasibility study.
   BJU Int. 2026 May 15. doi: 10.1111/bju.70316.
   PubMed     Abstract available
   
   
   
7. WEI N, Phillips RM, Kwon E, Stish BJ, et al
   Biochemical Recurrence Irradiation or Observation (BRIO) in patients with prostate cancer: protocol for a randomised control trial.
   BJU Int. 2026 May 12. doi: 10.1111/bju.70305.
   PubMed     Abstract available
   
   
   
8. TRINER D, Ginsburg KB, Moser A, Labardee C, et al
   Urologist and radiologist contributions to variation in prostate cancer detection at fusion biopsy.
   BJU Int. 2026 May 7. doi: 10.1111/bju.70308.
   PubMed     Abstract available
   
   
   
9. SHARIFI SHH, Williams A, Ryan JT, Ajami T, et al
   Multiparametric MRI in prostate cancer active surveillance: results from the Miami Active Surveillance Trial (MAST) trial.
   BJU Int. 2026 May 6. doi: 10.1111/bju.70303.
   PubMed     Abstract available
   
   
   
10. UGGE H, Daouacher G, Walden M
    The 5-year outcomes of a regional population-based PSA information and testing programme.
    BJU Int. 2026;137:877-885.
    PubMed     Abstract available
    
    
    April 2026
11. PICKERSGILL NA, Yu R, Vertosick EA, Fletcher SA, et al
    Diagnostic and prognostic utility of PSMA-PET/CT in node-metastatic prostate cancer.
    BJU Int. 2026 Apr 30. doi: 10.1111/bju.70280.
    PubMed     Abstract available
    
    
    
12. BRUINS SLOT AS, Sweere V, Heetman JG, Hermsen R, et al
    Nodal maximum standardised uptake value improves PSMA-PET/CT-based nodal staging in intermediate- and high-risk prostate cancer.
    BJU Int. 2026 Apr 20. doi: 10.1111/bju.70293.
    PubMed     Abstract available
    
    
    
13. MICHELETO JPC, Suzuki TA, Santos LA, Sales LP, et al
    Micro-ultrasonography- vs MRI-targeted biopsy in prostate cancer: Updated systematic review and meta-analysis.
    BJU Int. 2026 Apr 16. doi: 10.1111/bju.70270.
    PubMed     Abstract available
    
    
    
14. XU K, Shah N, Han DY, Koya M, et al
    Outcomes and progression predictors in a New Zealand active surveillance programme for prostate cancer.
    BJU Int. 2026 Apr 15. doi: 10.1111/bju.70276.
    PubMed     Abstract available
    
    
    
15. AL-KHANATY A, Chen D, Walbaum J, Hennes D, et al
    Guideline of guidelines: lutetium-177 PSMA radioligand therapy in advanced prostate cancer.
    BJU Int. 2026 Apr 14. doi: 10.1111/bju.70283.
    PubMed     Abstract available
    
    
    
16. KHANNA Y, Chinni V, Gnanasambantham K, Paul E, et al
    Does addition of multiparametric MRI to PSMA PET/CT improve diagnostic accuracy for biochemical recurrence after radical prostatectomy?
    BJU Int. 2026;137:619-628.
    PubMed     Abstract available
    
    
    March 2026
17. SUSHENTSEV N, Warren AY, Colling R, Verrill C, et al
    Long-term outcomes of cribriform-positive and cribriform-negative prostate cancer treated with radical prostatectomy in the ProtecT trial.
    BJU Int. 2026 Mar 27. doi: 10.1111/bju.70261.
    PubMed     Abstract available
    
    
    
18. WAGNER MC, Klemm J, Roessler N, Schulz RJ, et al
    Long-term patient-reported outcomes of open urorectal fistula repair after prostate cancer treatment.
    BJU Int. 2026 Mar 13. doi: 10.1111/bju.70233.
    PubMed     Abstract available
    
    
    
19. JACKSON SR, Yu P, Sowter S, Occhipinti S, et al
    The prostate cancer electronic health (eHealth) literacy instrument: a tool for eHealth design and patient communication.
    BJU Int. 2026 Mar 12. doi: 10.1111/bju.70225.
    PubMed     Abstract available
    
    
    
20. DELONGCHAMPS NB, Peltier A, Potiron E, Bladou F, et al
    Targeted microwave ablation of localised prostate cancer (VIOLETTE trial): a prospective multicentre study.
    BJU Int. 2026 Mar 11. doi: 10.1111/bju.70220.
    PubMed     Abstract available
    
    
    
21. MARQUIS A, Rastinehad AR
    Reply to 'Comment on novel MRI-US fusion with advanced annotation in focal cryoablation for prostate cancer'.
    BJU Int. 2026 Mar 6. doi: 10.1111/bju.70198.
    PubMed    
    
    
    
22. MA L, Lu R, Dong Z
    Comment on 'Novel MRI-US fusion with advanced annotation in focal cryoablation for prostate cancer: medium-term outcomes and learning curve insights'.
    BJU Int. 2026 Mar 6. doi: 10.1111/bju.70197.
    PubMed    
    
    
    
23. PALSHOF FK, Morch LS, Brasso K, Kroman N, et al
    Prostate-specific antigen testing and prostate cancer-related outcomes: a Danish nationwide study.
    BJU Int. 2026 Mar 4. doi: 10.1111/bju.70208.
    PubMed     Abstract available
    
    
    
24. BUHAS BA, Uleri A, Katzendorn O, Salin A, et al
    Transition to a digital perioperative pathway for robot-assisted radical prostatectomy: impact on patient outcomes and adherence.
    BJU Int. 2026;137:473-479.
    PubMed     Abstract available
    
    
    February 2026
25. MALPANI A, Ryan JT, Yu H, Soodana-Prakash N, et al
    Prediction Analysis of Microarray of 50 genes (PAM50) classifier validated for predicting prostate cancer progression in active surveillance: Miami Active Surveillance Trial (MAST).
    BJU Int. 2026 Feb 27. doi: 10.1111/bju.70202.
    PubMed     Abstract available
    
    
    
26. KANEKO M, Yang J, Magoulianitis V, Cacciamani GE, et al
    A transparent, lightweight and sustainable Green Learning AI model for prostate cancer detection on MRI.
    BJU Int. 2026 Feb 26. doi: 10.1111/bju.70203.
    PubMed     Abstract available
    
    
    
27. SHARMA A, Campbell T, Kanabar S, Soanes H, et al
    The PRAGMATIC pathway - PRostate cancer diAGnosis and MAnagement Triage In Clinical care.
    BJU Int. 2026 Feb 26. doi: 10.1111/bju.70191.
    PubMed     Abstract available
    
    
    
28. RUSBRIDGE J, Caglic I, Thavaraja L, Sushentsev N, et al
    The influence of age and the presence of prostate cancer on prostate volume, PSA and PSA density.
    BJU Int. 2026 Feb 23. doi: 10.1111/bju.70169.
    PubMed     Abstract available
    
    
    
29. NATHAN A, Parry MG, Cook A, Mayne E, et al
    Characteristics and outcomes of men presenting with complications of metastatic prostate cancer.
    BJU Int. 2026 Feb 17. doi: 10.1111/bju.70179.
    PubMed     Abstract available
    
    
    
30. AL-NADER M, Kesch C, Mahmoud O, Hadaschik BA, et al
    Patient-reported outcomes: active surveillance vs radical therapies in low-risk prostate cancer.
    BJU Int. 2026 Feb 16. doi: 10.1111/bju.70167.
    PubMed     Abstract available
    
    
    
31. DE LA CALLE CM, Baras AS, Lotan TL
    Digital pathology-based artificial intelligence algorithms in prostate cancer: inside the 'black box'.
    BJU Int. 2026 Feb 16. doi: 10.1111/bju.70164.
    PubMed     Abstract available
    
    
    
32. JANG JY, Lee JH, Pyo H, Park W, et al
    Risk of rectal bleeding with endorectal balloon use after hypofractionated intensity-modulated radiotherapy for prostate cancer.
    BJU Int. 2026 Feb 13. doi: 10.1111/bju.70175.
    PubMed     Abstract available
    
    
    
33. VEERASATIAN T, Arunsan P, Rattanapitoon SK, Rattanapitoon NK, et al
    Beyond sensitivity: artificial intelligence and micro-ultrasonography in prostate cancer detection.
    BJU Int. 2026 Feb 12. doi: 10.1111/bju.70112.
    PubMed    
    
    
    
34. NUNES P, Richaud F, Quantin C, Binquet C, et al
    Comparison of short-term complications after open, laparoscopic and robot-assisted radical prostatectomy.
    BJU Int. 2026;137:348-359.
    PubMed     Abstract available
    
    
    
35. SHIRAFUJI T, Yamada Y, Sato K, Xue Z, et al
    Discordance between PSA level and bone metastatic volume is associated with unfavourable prognosis.
    BJU Int. 2026;137:368-375.
    PubMed     Abstract available
    
    
    
36. YOUNG GJ, Walsh EI, Lane JA, Donovan JL, et al
    Patient-reported outcome measures in prostate research: a scoping review.
    BJU Int. 2026;137:241-250.
    PubMed     Abstract available
    
    
    January 2026
37. KATO T, Yokomizo A, Matsumoto R, Fukuhara H, et al
    Active surveillance for patients with prostate cancer aged >/=75 years: the Prostate Cancer Research International: Active Surveillance (PRIAS)-JAPAN study.
    BJU Int. 2026 Jan 29. doi: 10.1111/bju.70156.
    PubMed     Abstract available
    
    
    
38. KAM J, Hanna B, Jackson S, McCombie S, et al
    Focal therapy using a novel cooled laser device for prostate cancer: early trial results.
    BJU Int. 2026 Jan 28. doi: 10.1111/bju.70150.
    PubMed     Abstract available
    
    
    
39. AL-HAMMOURI T, Brembilla G, Brizmohun M, Tuazon J, et al
    The 'Comparison of diagnostic accuracy of Luminal Index and standard of care MRI for Accelerated deTEction of prostate cancer' (CLIMATE) trial protocol.
    BJU Int. 2026 Jan 25. doi: 10.1111/bju.70108.
    PubMed     Abstract available
    
    
    
40. KNIEP C, Maurer T, Hartwieg BF, Mandel P, et al
    Diagnostic accuracy and outcomes of lymph node staging in intermediate-risk prostate cancer.
    BJU Int. 2026 Jan 23. doi: 10.1111/bju.70155.
    PubMed     Abstract available
    
    
    
41. BERGEROT PG, Bergerot CD, Schmitz KH, Pal S, et al
    Enhancing quality of life in patients with prostate cancer through a remote exercise programme.
    BJU Int. 2026 Jan 16. doi: 10.1111/bju.70152.
    PubMed    
    
    
    
42. ZAURITO P, Garmo H, Gedeborg R, Alhberg M, et al
    Incidence and prognostic implications of PSA relapse after radical radiotherapy for prostate cancer: a population-based study.
    BJU Int. 2026 Jan 15. doi: 10.1111/bju.70148.
    PubMed     Abstract available
    
    
    
43. SEMWAL BC, Yadav S, Gupta PS
    Comment on 'Prostate zonal impact of 5alpha-reductase inhibitors on multiparametric MRI characteristics and detection of prostate cancer'.
    BJU Int. 2026 Jan 8. doi: 10.1111/bju.70138.
    PubMed    
    
    
    
44. SANDHU K, Wells C, Lawrentschuk N
    Emerging radiotracers in prostate cancer: opportunities and challenges.
    BJU Int. 2026 Jan 4. doi: 10.1111/bju.70132.
    PubMed    
    
    
    
45. 
    Prostate cancer: screening, diagnosis and treatment.
    BJU Int. 2026;137:10-11.
    PubMed    
    
    
    
46. MARMIROLI A, Di Bello F, Penaranda NR, Longoni M, et al
    Adverse in-hospital outcomes in patients with paraplegia who undergo radical prostatectomy.
    BJU Int. 2026;137:209-215.
    PubMed     Abstract available
    
    
    December 2025
47. BATOUCHE AO, Czeizler E, Lehto TP, Erickson A, et al
    Comparable recurrence risk for MRI-detected Gleason Grade Group (GG) 2 and systematic biopsy-detected GG1 prostate cancer.
    BJU Int. 2025 Dec 14. doi: 10.1111/bju.70109.
    PubMed     Abstract available
    
    
    
48. CRISAFI D, Jiang J, Bolton D, Ischia J, et al
    What are we missing? Identifying clinically significant prostate cancer among patients with low PSA: the utility of the free-to-total PSA ratio.
    BJU Int. 2025 Dec 8. doi: 10.1111/bju.70110.
    PubMed    
    
    
    
49. RUSH HL, Merrick S, Marshall J, Deighan J, et al
    Preferences between three options for androgen deprivation therapy: a focus group study.
    BJU Int. 2025;136:1037-1047.
    PubMed     Abstract available
    
    
    November 2025
50. VAN DEN EYNDE L, Ost P, Lumen N
    Authors' reply to: comment on 'Feasibility of randomisation to radical prostatectomy or standard care in patients with metastatic prostate cancer'.
    BJU Int. 2025 Nov 27. doi: 10.1111/bju.70098.
    PubMed    
    
    
    
51. ZHAO K, Zhou Z, Dong Z
    Comment on 'Feasibility of randomisation to radical prostatectomy or standard care in patients with metastatic prostate cancer'.
    BJU Int. 2025 Nov 27. doi: 10.1111/bju.70097.
    PubMed    
    
    
    
52. LU G, Wang J, Zheng W, Yu H, et al
    Immune checkpoint inhibitor nivolumab induces durable response in microsatellite instability-high and DNA damage repair-deficient metastatic castration-resistant prostate cancer.
    BJU Int. 2025 Nov 14. doi: 10.1111/bju.70084.
    PubMed    
    
    
    
53. SOON YY, Marschner IC, Schou IM, Sweeney CJ, et al
    Target trial emulation of early docetaxel and enzalutamide for metastatic hormone-sensitive prostate cancer.
    BJU Int. 2025 Nov 5. doi: 10.1111/bju.70065.
    PubMed     Abstract available
    
    
    
54. DAS A, Bigarella M, Brackman K, Allen GO, et al
    Prostate zonal impact of 5alpha-reductase inhibitors on multiparametric MRI characteristics and detection of prostate cancer.
    BJU Int. 2025 Nov 5. doi: 10.1111/bju.70067.
    PubMed     Abstract available
    
    
    
55. BUSHATI Y, Guo AA, Muston BT, Bushati A, et al
    Focal laser ablation in prostate cancer: a systematic review and meta-analysis.
    BJU Int. 2025 Nov 4. doi: 10.1111/bju.70064.
    PubMed     Abstract available
    
    
    
56. HANDA N, Shore ND, Cooperberg MR, Davicioni E, et al
    Transcriptome profiling of prostatic tumours from ENACT trial patients with or without enzalutamide.
    BJU Int. 2025;136:920-929.
    PubMed     Abstract available
    
    
    
57. UEKI H, Uemura M, Chinzei K, Takahashi K, et al
    Developing an artificial intelligence model for phase recognition in robot-assisted radical prostatectomy.
    BJU Int. 2025;136:891-901.
    PubMed     Abstract available
    
    
    October 2025
58. MA L, Lu R, Dong Z
    Comment on 'Renal, bladder and prostate cancer surgery outcomes with respect to team familiarity'.
    BJU Int. 2025 Oct 23. doi: 10.1111/bju.70032.
    PubMed    
    
    
    
59. CANNOLETTA D, Stabile A, Quarta L, Barletta F, et al
    Utility of MRI perilesional biopsy in prostate cancer: impact of the Prostate Imaging-Reporting and Data System and biopsy history.
    BJU Int. 2025 Oct 13. doi: 10.1111/bju.70027.
    PubMed     Abstract available
    
    
    
60. SIGHINOLFI MC, Pallotta G, Assumma S, Panio E, et al
    A novel comprehensive cancer genome profiling for non-metastatic prostate cancer: study protocol with FPG500 to detect actionable alterations representative of progressive disease.
    BJU Int. 2025 Oct 10. doi: 10.1111/bju.70019.
    PubMed     Abstract available
    
    
    
61. MARQUIS A, Schwartz MJ, Armache A, Solosky K, et al
    Novel MRI-US fusion with advanced annotation in focal cryoablation for prostate cancer: medium-term outcomes and learning curve insights.
    BJU Int. 2025 Oct 9. doi: 10.1111/bju.70014.
    PubMed     Abstract available
    
    
    
62. GILL S, Chen R, Lamb BW, Moore CM, et al
    Interventions for patients with prostate cancer on active surveillance: a narrative review.
    BJU Int. 2025 Oct 6. doi: 10.1111/bju.70005.
    PubMed     Abstract available
    
    
    
63. SCUDERI S, Gandaglia G, Briganti A, Montorsi F, et al
    Re: 'Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review'.
    BJU Int. 2025 Oct 3. doi: 10.1111/bju.70024.
    PubMed    
    
    
    
64. HALL R, Ball R, Bancroft E, Eeles R, et al
    Systematic review of PSA reference intervals in the gender diverse population with prostates.
    BJU Int. 2025;136:568-577.
    PubMed     Abstract available
    
    
    
65. VISSCHER J, Bonevski B, O'Callaghan M
    The association of smoking with urinary and sexual function recovery following radical prostatectomy.
    BJU Int. 2025;136:647-656.
    PubMed     Abstract available
    
    
    
66. LEWICKI P, Ginsburg K, Mmonu N, Labardee C, et al
    What is lost in an average? Identifying distinct post-radical prostatectomy functional recovery profiles.
    BJU Int. 2025;136:633-639.
    PubMed     Abstract available
    
    
    
67. HUANG S, Chen DC, Qu L, Papa N, et al
    A meta-analysis of Retzius-sparing and hood-technique robot-assisted radical prostatectomy.
    BJU Int. 2025;136 Suppl 2:S18-S27.
    PubMed     Abstract available
    
    
    September 2025
68. BONADDIO J, Carll J, Eapen R, Sathianathen N, et al
    The role of PSMA PET/CT in staging patients with intermediate-risk prostate cancer.
    BJU Int. 2025 Sep 30. doi: 10.1111/bju.70015.
    PubMed     Abstract available
    
    
    
69. VAN DEN EYNDE L, Ost P, Verla W, Everaerts W, et al
    Feasibility of randomisation to radical prostatectomy or standard care in patients with metastatic prostate cancer.
    BJU Int. 2025 Sep 20. doi: 10.1111/bju.70006.
    PubMed     Abstract available
    
    
    
70. ZAURITO P, Westerberg M, Garmo H, Gedeborg R, et al
    Urinary tract events after radical radiotherapy (RT) for prostate cancer according to pre-RT International Prostate Symptom Score.
    BJU Int. 2025 Sep 12. doi: 10.1111/bju.16927.
    PubMed     Abstract available
    
    
    
71. DAUNGSUPAWONG H, Wiwanitkit V
    Comment on 'Socioeconomic disparities in prostate cancer screening: the impact of the Area Deprivation Index on PSA screening frequency'.
    BJU Int. 2025 Sep 4. doi: 10.1111/bju.16922.
    PubMed    
    
    
    
72. BERTINI A, Cirulli GO, Stephens A, Finocchiaro A, et al
    Reply to 'Comment on Bertini et al.: area deprivation and PSA screening disparities' and 'Comment on socioeconomic disparities in prostate cancer screening: the impact of the Area Deprivation Index on PSA screening frequency'.
    BJU Int. 2025 Sep 4. doi: 10.1111/bju.16924.
    PubMed    
    
    
    
73. ROBERTS IA, Cumberbatch MG, Catto JWF
    Renal, bladder and prostate cancer surgery outcomes with respect to team familiarity.
    BJU Int. 2025 Sep 4. doi: 10.1111/bju.16920.
    PubMed     Abstract available
    
    
    
74. VLAMING M, Koole W, van Moorselaar RJA, Bleiker EMA, et al
    Prevalence of germline pathogenic variants in 779 patients with metastatic prostate cancer.
    BJU Int. 2025 Sep 2. doi: 10.1111/bju.16916.
    PubMed     Abstract available
    
    
    
75. COLLINS KK, Virdee PS, Roberts N, Oke JL, et al
    Guideline of guidelines: a critical appraisal of the evidence for PSA retesting intervals.
    BJU Int. 2025;136:372-384.
    PubMed     Abstract available
    
    
    
76. BERRENS AC, Buckle T, van Oosterom MN, Slof LJ, et al
    Renal clearance of fluorescent agents can compromise image-guided surgery along the urinary tract.
    BJU Int. 2025;136:515-522.
    PubMed     Abstract available
    
    
    
77. LENI R, Tin AL, Liso N, Carlsson SV, et al
    Magnetic resonance imaging for long-term active surveillance biopsy decision-making.
    BJU Int. 2025;136:500-506.
    PubMed     Abstract available
    
    
    
78. LEPOR H, Persily J, Parry S, Rapoport E, et al
    Routine prostate biopsies not needed after cryotherapy if surveillance MRI is normal.
    BJU Int. 2025;136:447-451.
    PubMed     Abstract available
    
    
    
79. KHAN N, Prezzi D, Raison N, Shepherd A, et al
    Impact of three-dimensional prostate models during robot-assisted radical prostatectomy on surgical margins and functional outcomes.
    BJU Int. 2025;136:420-428.
    PubMed     Abstract available
    
    
    August 2025
80. SATAPATHY P, Mehta R, Sah R
    Comment on 'Clinical features of medication-related osteonecrosis of the jaw in prostate cancer management'.
    BJU Int. 2025 Aug 28. doi: 10.1111/bju.16914.
    PubMed    
    
    
    
81. ZHOU SR, Zhang L, Choi MH, Vesal S, et al
    ProMUS-NET: Artificial intelligence detects more prostate cancer than urologists on micro-ultrasonography.
    BJU Int. 2025 Aug 27. doi: 10.1111/bju.16892.
    PubMed     Abstract available
    
    
    
82. ITO K, Mori K, Kumar R, Sabnis RB, et al
    Global viewpoints: evolving epidemiology and treatment patterns of prostate cancer in Asia.
    BJU Int. 2025 Aug 24. doi: 10.1111/bju.16900.
    PubMed     Abstract available
    
    
    
83. CHIAM K, Bang A, Nair-Shalliker V, Caruana M, et al
    Treatment variations in localised prostate cancer in Australia and New Zealand: a registry study.
    BJU Int. 2025 Aug 22. doi: 10.1111/bju.16896.
    PubMed     Abstract available
    
    
    
84. CHONG B, Chen K
    Reply to 'A mitochondrion-centric approach to guide treatment de-escalation in advanced prostate cancer' by Su et al.
    BJU Int. 2025 Aug 22. doi: 10.1111/bju.16898.
    PubMed    
    
    
    
85. SU PJ, Shao IH, Lin YH
    A mitochondrion-centric approach to guide treatment de-escalation in advanced prostate cancer.
    BJU Int. 2025 Aug 22. doi: 10.1111/bju.16897.
    PubMed    
    
    
    
86. FLETCHER SA, Macura KJ, Pavlovich CP
    Author response to comment on 'Clinically significant prostate cancer detected by systematic biopsy in patients with MRI lesions'.
    BJU Int. 2025 Aug 17. doi: 10.1111/bju.16869.
    PubMed    
    
    
    
87. OLIVIER J, Vertosick E, Delobel L, Bommelaere T, et al
    Quantification of prostate cancer Gleason pattern 4 to predict oncological outcome.
    BJU Int. 2025 Aug 7. doi: 10.1111/bju.16884.
    PubMed     Abstract available
    
    
    
88. SANAPALA K, Mehta R, Sah R
    Comment on 'Clinically significant prostate cancer detected by systematic biopsy in patients with MRI lesions'.
    BJU Int. 2025 Aug 2. doi: 10.1111/bju.16868.
    PubMed    
    
    
    
89. SANTUCCI J, Stapleton P, Perera M, Ischia J, et al
    Oncological safety of testosterone replacement therapy in men with localised prostate cancer: a systematic review of observational studies.
    BJU Int. 2025 Aug 1. doi: 10.1111/bju.16870.
    PubMed     Abstract available
    
    
    July 2025
90. BERTINI A, Cirulli GO, Stephens A, Finocchiaro A, et al
    Socioeconomic disparities in prostate cancer screening: the impact of the Area Deprivation Index on PSA screening frequency.
    BJU Int. 2025 Jul 30. doi: 10.1111/bju.16875.
    PubMed     Abstract available
    
    
    
91. CARLL J, Shi W, Perera M, Lawrentschuk N, et al
    Guideline of guidelines: PSMA PET in staging newly diagnosed intermediate-risk prostate cancer.
    BJU Int. 2025 Jul 24. doi: 10.1111/bju.16872.
    PubMed     Abstract available
    
    
    
92. GOTO Y, Urabe F, Ogihara Y, Nakata M, et al
    Clinical features of medication-related osteonecrosis of the jaw in prostate cancer management.
    BJU Int. 2025 Jul 19. doi: 10.1111/bju.16860.
    PubMed     Abstract available
    
    
    
93. ZHANG K, Teoh J, Laguna P, de la Rosette J, et al
    Response to Veldi et al.: 'The diagnostic value of MRI for persistent prostate cancer following irreversible electroporation focal therapy' - a critical appraisal.
    BJU Int. 2025 Jul 15. doi: 10.1111/bju.16840.
    PubMed    
    
    
    
94. 
    Prostate cancer: detection, treatment and follow-up.
    BJU Int. 2025;136:2-3.
    PubMed    
    
    
    
95. EID N, Lepor H
    Incidence, surveillance and natural history of high-grade prostatic epithelial neoplasia in the era of multiparametric MRI and targeted biopsy.
    BJU Int. 2025;136:159-164.
    PubMed     Abstract available
    
    
    
96. HAGMAN A, Lantz A, Grannas D, Carlsson S, et al
    Positive surgical margin and oncological outcomes after robot-assisted radical prostatectomy in different Cancer of the Prostate Risk Assessment risk groups.
    BJU Int. 2025;136:135-142.
    PubMed     Abstract available
    
    
    
97. ROBERTS MJ, Arora S, Yao HH, Hogan D, et al
    Transperineal prostate biopsy under local vs general anaesthesia: a cost-effectiveness analysis.
    BJU Int. 2025;136:128-134.
    PubMed     Abstract available
    
    
    
98. KHATTAK A, Ruta D, Patkar V, Popert R, et al
    Artificial intelligence-driven streamlining of prostate cancer multidisciplinary team recommendations in a tertiary NHS centre in the UK.
    BJU Int. 2025 Jul 1. doi: 10.1111/bju.16845.
    PubMed     Abstract available
    
    
    June 2025
99. SCHIEDA N, Morash C, Lavallee LT, Flood TA, et al
    Prostate cancer detection by MRI-ultrasonography fusion transperineal vs transrectal biopsy: a randomised control trial.
    BJU Int. 2025 Jun 27. doi: 10.1111/bju.16831.
    PubMed     Abstract available
    
    
    
100. VELDI VDK, Mehta R, Sah R
     Comment on 'The diagnostic value of MRI for persistent prostate cancer following irreversible electroporation focal therapy'.
     BJU Int. 2025 Jun 26. doi: 10.1111/bju.16841.
     PubMed    
     
     
     
101. BYRNE MHV, Anbarasan T, Browning L, Woodcock DJ, et al
     What spatial omics is teaching us about field cancerisation in prostate and bladder cancer.
     BJU Int. 2025 Jun 25. doi: 10.1111/bju.16830.
     PubMed     Abstract available
     
     
     
102. TOH EA, White J, Clarke J, Hider P, et al
     Variation in prostate cancer assessment and management between Maori and non-Maori in New Zealand.
     BJU Int. 2025 Jun 13. doi: 10.1111/bju.16805.
     PubMed     Abstract available
     
     
     
103. FLETCHER SA, Alshak MN, Lee S, Singla N, et al
     Clinically significant prostate cancer detected by systematic biopsy in patients with MRI lesions.
     BJU Int. 2025 Jun 12. doi: 10.1111/bju.16816.
     PubMed     Abstract available
     
     
     May 2025
104. LIU J, Woon DTS, Perera M, Lawrentschuk N, et al
     Active surveillance in prostate cancer: when to exit and what are the options?
     BJU Int. 2025 May 19. doi: 10.1111/bju.16744.
     PubMed    
     
     
     
105. ALSHAK MN, Higgins MI, Grutman AJ, Campbell J, et al
     Prostate cancer active surveillance in solid organ transplant: a matched study and literature review.
     BJU Int. 2025 May 14. doi: 10.1111/bju.16777.
     PubMed     Abstract available
     
     
     
106. 
     Recent key papers in prostate cancer.
     BJU Int. 2025;135:710-711.
     PubMed    
     
     
     
107. CHEN DC, Huang S, Papa N, Siva S, et al
     Impact of intraprostatic PSMA maximum standardised uptake value following prostatectomy: a systematic review and meta-analysis.
     BJU Int. 2025;135:720-732.
     PubMed     Abstract available
     
     
     
108. GROSSMANN NC, Aschwanden FJ, Cornelius J, Malkmus C, et al
     Impact of patient positioning during surgery on neuropathies after robot-assisted laparoscopic radical prostatectomy: a randomised controlled trial.
     BJU Int. 2025;135:802-809.
     PubMed     Abstract available
     
     
     April 2025
109. SILAGY AW, Woon DTS, Kostos L, Bernardino R, et al
     Percentage of free to total PSA as a biomarker of survival in metastatic castration-resistant prostate cancer.
     BJU Int. 2025 Apr 25. doi: 10.1111/bju.16751.
     PubMed     Abstract available
     
     
     
110. PYRGIDIS N, Chaloupka M, Ebner B, Volz Y, et al
     Perioperative complications of focal therapy for prostate cancer: results from the GeRmAn Nationwide inpatient Data (GRAND) study.
     BJU Int. 2025 Apr 19. doi: 10.1111/bju.16746.
     PubMed     Abstract available
     
     
     
111. HO P, Kaufmann B, Gorin MA
     Case of the Month from the Icahn School of Medicine at Mount Sinai, New York, NY: MRI/TRUS fusion-guided biopsy of a local prostate cancer recurrence using the bladder for image registration.
     BJU Int. 2025 Apr 14. doi: 10.1111/bju.16698.
     PubMed    
     
     
     
112. SUSHENTSEV N, Comune R, Sinci KA, Blyuss O, et al
     A 10-year analysis of MRI-driven prostate cancer diagnosis and active surveillance: trends and implications.
     BJU Int. 2025 Apr 14. doi: 10.1111/bju.16743.
     PubMed    
     
     
     
113. DE VOS II, Marenghi C, Badenchini F, Boeve ER, et al
     Long-term outcomes of active surveillance for Grade Group 1 prostate cancer and the impact of the use of MRI on overtreatment.
     BJU Int. 2025 Apr 14. doi: 10.1111/bju.16727.
     PubMed     Abstract available
     
     
     
114. OLSSON K, Delilovic S, Enelius MB, Hagglund A, et al
     Men's experiences of the Swedish Organised Prostate Cancer Testing programme: a qualitative study.
     BJU Int. 2025 Apr 6. doi: 10.1111/bju.16735.
     PubMed     Abstract available
     
     
     
115. ZHANG K, Teoh J, Laguna P, Dominguez-Escrig J, et al
     The diagnostic value of MRI for persistent prostate cancer following irreversible electroporation focal therapy.
     BJU Int. 2025 Apr 4. doi: 10.1111/bju.16720.
     PubMed     Abstract available
     
     
     
116. 
     Correction to "Prostate cancer in transgender women: what does a urologist need to know?".
     BJU Int. 2025 Apr 3. doi: 10.1111/bju.16723.
     PubMed    
     
     
     
117. NOLSOE AB, Logager V, Boesen L, Ostergren PB, et al
     Association of bi-parametric MRI measures with continence after robot-assisted radical prostatectomy.
     BJU Int. 2025;135:603-610.
     PubMed     Abstract available
     
     
     
118. ENGESSER C, Brantner P, Gahl B, Walter M, et al
     3D-printed model for resection of positive surgical margins in robot-assisted prostatectomy.
     BJU Int. 2025;135:657-667.
     PubMed     Abstract available
     
     
     March 2025
119. KAM J, Chalasani V, Goolam AS, Bergersen P, et al
     Reduced prostate cancer screening has a negative impact on stage migration: the Australian experience.
     BJU Int. 2025 Mar 6. doi: 10.1111/bju.16654.
     PubMed     Abstract available
     
     
     
120. MAYOR N, Light A, Silvanto A, Cullen E, et al
     Fluorescence confocal microscopy for margin assessment in prostatectomy: IP8-FLUORESCE study protocol.
     BJU Int. 2025;135:502-509.
     PubMed     Abstract available
     
     
     
121. BOESEN L, Norgaard N, Bisbjerg R, Logager V, et al
     Clinical value of contralateral biopsies in men with unilateral MRI foci undergoing targeted biopsy.
     BJU Int. 2025;135:465-472.
     PubMed     Abstract available
     
     
     February 2025
122. ORTNER G, Falkenbach F, Kachanov M, Inderhees T, et al
     External validation of a nomogram for unilateral pelvic lymph node dissection in prostate cancer.
     BJU Int. 2025 Feb 20. doi: 10.1111/bju.16687.
     PubMed     Abstract available
     
     
     
123. XIE S, Liu J, Shen B, Xu H, et al
     Salvage low-dose vs high-dose brachytherapy for radio-recurrent prostate cancer.
     BJU Int. 2025 Feb 9. doi: 10.1111/bju.16639.
     PubMed     Abstract available
     
     
     
124. RODRIGUEZ-SANCHEZ L, Cathelineau X, de Reijke TM, Stricker P, et al
     Refining partial gland ablation for localised prostate cancer: the FALCON project.
     BJU Int. 2025 Feb 4. doi: 10.1111/bju.16669.
     PubMed     Abstract available
     
     
     
125. 
     Outcomes of prostate cancer treatments.
     BJU Int. 2025;135:184-185.
     PubMed    
     
     
     
126. SOPUTRO NA, Ramos-Carpinteyro R, Chavali JS, Pedraza AM, et al
     Predictors for selection of outpatient single-port robot-assisted laparoscopic radical prostatectomy.
     BJU Int. 2025;135:249-259.
     PubMed     Abstract available
     
     
     January 2025
127. GNANAPRAGASAM VJ, Keates A, Lophatananon A, Thankapannair V, et al
     The 5-year results of the Stratified Cancer Active Surveillance programme for men with prostate cancer.
     BJU Int. 2025 Jan 29. doi: 10.1111/bju.16666.
     PubMed     Abstract available
     
     
     
128. PYLVALAINEN J, Talala K, Raitanen J, Rannikko A, et al
     Association of prostate-specific antigen density with prostate cancer mortality after a benign systematic prostate biopsy result.
     BJU Int. 2025 Jan 22. doi: 10.1111/bju.16641.
     PubMed     Abstract available
     
     
     
129. CHONG B, Saad M, Chong TW, Thng J, et al
     Selective treatment de-escalation in advanced prostate cancer: have we come full circle?
     BJU Int. 2025 Jan 2. doi: 10.1111/bju.16632.
     PubMed     Abstract available
     
     
     
130. CHIU PK, Liu AQ, Lau SY, Teoh JY, et al
     A 2-year prospective evaluation of the Prostate Health Index in guiding biopsy decisions in a large cohort.
     BJU Int. 2025;135:71-77.
     PubMed     Abstract available
     
     
     December 2024
131. OKHAWERE KE, Razdan S, Beksac AT, Saini I, et al
     Novel bioabsorbable, low-dose rate brachytherapy device (CivaSheet((R))) with radical prostatectomy and adjuvant external beam radiation for the management of prostate cancer.
     BJU Int. 2024 Dec 9. doi: 10.1111/bju.16617.
     PubMed     Abstract available
     
     
     
132. GELIKMAN DG, Azar WS, Yilmaz EC, Lin Y, et al
     A Prostate Imaging-Reporting and Data System version 2.1-based predictive model for clinically significant prostate cancer diagnosis.
     BJU Int. 2024 Dec 9. doi: 10.1111/bju.16616.
     PubMed     Abstract available
     
     
     
133. NOURMOHAMMADI ABADCHI S, Salles DC, Flannery C, Sama V, et al
     Association of Genomic Prostate Score at positive margin with recurrence after radical prostatectomy.
     BJU Int. 2024;134:939-944.
     PubMed     Abstract available
     
     
     
134. MERSEBURGER AS, Agarwal N, Bjartell A, Uemura H, et al
     Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy.
     BJU Int. 2024;134:982-991.
     PubMed     Abstract available
     
     
     
135. CRISAFI D, Wong BNX, Bolton D, Ischia J, et al
     Urologist underutilisation of androgen receptor pathway inhibitors for metastatic hormone-sensitive prostate cancer.
     BJU Int. 2024;134 Suppl 2:12-13.
     PubMed    
     
     
     
136. ROBERTS MJ, Papa N, Veerman H, de Bie K, et al
     Prediction of biochemical recurrence after radical prostatectomy from primary tumour characteristics.
     BJU Int. 2024;134 Suppl 2.
     PubMed     Abstract available
     
     
     November 2024
137. MARTIN A, Mahmoud AM, Britton CJ, Fadel A, et al
     In-field prostate cancer recurrence following radical prostatectomy and salvage radiation.
     BJU Int. 2024 Nov 30. doi: 10.1111/bju.16598.
     PubMed     Abstract available
     
     
     
138. SII S, Papa N, Yiu TW, Tempo J, et al
     Utility of PSA free-to-total ratio for clinically significant prostate cancer in men with a PSA level of <4 ng/mL.
     BJU Int. 2024 Nov 28. doi: 10.1111/bju.16597.
     PubMed     Abstract available
     
     
     
139. THIMANSSON E, Axen E, Jaderling F, Styrke J, et al
     A novel approach to integrated prostate cancer diagnostics: insights from MRI, prostate biopsy, and pathology reports in a pilot study.
     BJU Int. 2024 Nov 12. doi: 10.1111/bju.16582.
     PubMed    
     
     
     
140. RAVAL AD, Chen S, Littleton N, Constantinovici N, et al
     Real-world use of androgen-deprivation therapy intensification for metastatic hormone-sensitive prostate cancer: a systematic review.
     BJU Int. 2024 Nov 12. doi: 10.1111/bju.16577.
     PubMed     Abstract available
     
     
     
141. RANS K, Goffin K, Joniau S, Daugaard G, et al
     The impact of progression-directed therapy on survival in metastatic castration-refractory prostate cancer: MEDCARE phase 3 trial.
     BJU Int. 2024 Nov 6. doi: 10.1111/bju.16574.
     PubMed     Abstract available
     
     
     
142. TAKAHASHI T
     The first step in shared decision-making for prostate cancer screening.
     BJU Int. 2024 Nov 6. doi: 10.1111/bju.16580.
     PubMed    
     
     
     
143. LIU J, Cundy TP, Woon DTS, Desai N, et al
     A systematic review on artificial intelligence evaluating PSMA PET scan for intraprostatic cancer.
     BJU Int. 2024;134:714-722.
     PubMed     Abstract available
     
     
     
144. MUSI G, Mistretta FA, Ivanova M, de Cobelli O, et al
     Evaluation of margins during radical prostatectomy: confocal microscopy vs frozen section analysis.
     BJU Int. 2024;134:773-780.
     PubMed     Abstract available
     
     
     October 2024
145. DE ANGELIS M, Siech C, Di Bello F, Rodriguez Penaranda N, et al
     Mortality rates in radical cystectomy patients with bladder cancer after radiation therapy for prostate cancer.
     BJU Int. 2024 Oct 27. doi: 10.1111/bju.16571.
     PubMed     Abstract available
     
     
     
146. LI T, Graham PL, Cao B, Nalavenkata S, et al
     Accuracy of MRI in detecting seminal vesicle invasion in prostate cancer: a systematic review and meta-analysis.
     BJU Int. 2024 Oct 22. doi: 10.1111/bju.16547.
     PubMed     Abstract available
     
     
     
147. ANG ZY, Kong YL, Md Nesran ZN, Lee SWH, et al
     Efficacy of decision aid delivery modes in prostate cancer screening: umbrella review and network meta-analysis.
     BJU Int. 2024 Oct 14. doi: 10.1111/bju.16545.
     PubMed     Abstract available
     
     
     
148. LAZAROVICH A, Kristof TW, Steadman S, Dahmen AS, et al
     Prostate cancer and solid organ transplantation: patient management and outcomes.
     BJU Int. 2024 Oct 9. doi: 10.1111/bju.16558.
     PubMed     Abstract available
     
     
     
149. GONZALEZ-SAN SEGUNDO C, Lopez Campos F, Gomez Iturriaga A, Rodriguez A, et al
     A randomised trial of short- vs long-term androgen deprivation with salvage radiotherapy for biochemical failure following radical prostatectomy: URONCOR 06-24.
     BJU Int. 2024;134:568-577.
     PubMed     Abstract available
     
     
     
150. KINNEAR N, Fonseca PC, Ogbechie C, Adam S, et al
     Impact of frozen section on long-term outcomes in robot-assisted laparoscopic prostatectomy.
     BJU Int. 2024;134:608-614.
     PubMed     Abstract available
     
     
     
151. TAYA M, Behr SC, Westphalen AC
     Perspectives on technology: Prostate Imaging-Reporting and Data System (PI-RADS) interobserver variability.
     BJU Int. 2024;134:510-518.
     PubMed     Abstract available
     
     
     
152. SAHNI DS, Morrison J, Leung HY
     Grid-based cognitive diagnostic prostatic biopsy without transrectal ultrasonography.
     BJU Int. 2024;134:659-663.
     PubMed    
     
     
     September 2024
153. FANG AM, Gregg JR, Pettaway C, Ma J, et al
     Whole-body MRI for staging prostate cancer: a narrative review.
     BJU Int. 2024 Sep 22. doi: 10.1111/bju.16514.
     PubMed     Abstract available
     
     
     
154. 
     Advances in the detection and treatment of prostate cancer plus d-mannose for the prevention of recurrent UTIs.
     BJU Int. 2024;134:321-322.
     PubMed    
     
     
     
155. REIJNDERS-BOERBOOM GTJA, Jacobs LMC, Helder LS, Panhuizen IF, et al
     Recovery and immune function after low pressure pneumoperitoneum during robot-assisted radical prostatectomy: a randomised controlled trial.
     BJU Int. 2024;134:416-425.
     PubMed     Abstract available
     
     
     
156. TOUZANI A, D'Agate D, Kesch C, Calleris G, et al
     One-year outcomes of same-day-discharge robot-assisted radical prostatectomy.
     BJU Int. 2024;134:380-382.
     PubMed    
     
     
     
157. OUCHI M, Kitta T, Chiba H, Higuchi M, et al
     Physiotherapy for continence and muscle function in prostatectomy: a randomised controlled trial.
     BJU Int. 2024;134:398-406.
     PubMed     Abstract available
     
     
     
158. BATES AS, Sharma AD, Camilleri P, Browning L, et al
     'Case of the Month' from the Department of Urology, Oxford University Hospitals, Oxford, UK: stereotactic radiotherapy to the vas deferens for PSMA-PET CT detected local recurrence 10 years after radical prostatectomy.
     BJU Int. 2024;134:377-379.
     PubMed    
     
     
     August 2024
159. TAKAHASHI T
     Observational study on screen-detected prostate cancer: case series of empirical clinical practice.
     BJU Int. 2024 Aug 29. doi: 10.1111/bju.16525.
     PubMed    
     
     
     
160. ONG WL, Krishnaprasad K, Bensley J, Steeper M, et al
     Population-based prostate cancer outcomes registries - what have we learned and where are we heading?
     BJU Int. 2024 Aug 19. doi: 10.1111/bju.16487.
     PubMed    
     
     
     
161. GEBOERS B, Scheltema MJ, Jung J, Bakker J, et al
     Irreversible electroporation of localised prostate cancer downregulates immune suppression and induces systemic anti-tumour T-cell activation - IRE-IMMUNO study.
     BJU Int. 2024 Aug 5. doi: 10.1111/bju.16496.
     PubMed     Abstract available
     
     
     
162. JACEWICZ M, Rud E, Lauritzen P, Baco E, et al
     Non-infectious adverse events of transperineal prostate biopsies performed under local anaesthesia.
     BJU Int. 2024;134:300-306.
     PubMed     Abstract available
     
     
     
163. FANKHAUSER CD, Malkmus C, Aschwanden F, Baumeister P, et al
     'Igloo' technique for robot-assisted radical prostatectomy - maximum nerve sparing for early recovery of continence and sexual function.
     BJU Int. 2024;134:307-311.
     PubMed    
     
     
     
164. ABUELNAGA M, Gendy R, Yao M, Phelan C, et al
     Impact of definitions on continence outcomes in a series of 1000 robot-assisted radical prostatectomies, time for an internationally agreed definition?
     BJU Int. 2024;134:197-200.
     PubMed    
     
     
     
165. NG KL, Giona S, Barber N
     Feasibility of Aquablation prostate surgery performed as day cases.
     BJU Int. 2024;134:185-186.
     PubMed    
     
     
     July 2024
166. BANCROFT EK
     Response to BJU-2024-0780: RE: The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers.
     BJU Int. 2024 Jul 26. doi: 10.1111/bju.16490.
     PubMed    
     
     
     
167. DAUNGSUPAWONG H, Wiwanitkit V
     RE: 'The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers'.
     BJU Int. 2024 Jul 26. doi: 10.1111/bju.16489.
     PubMed    
     
     
     
168. YANG J, Xiong X, Wei Q, Yang L, et al
     Acupuncture: a promising adjuvant strategy for pain management among the patients with prostate cancer.
     BJU Int. 2024 Jul 17. doi: 10.1111/bju.16467.
     PubMed    
     
     
     
169. MAURER J, Ambrosini F, Chen Y, Schroeder S, et al
     Acupuncture: a strategy for pain management among patients with prostate cancer - authors' reply.
     BJU Int. 2024 Jul 16. doi: 10.1111/bju.16468.
     PubMed    
     
     
     
170. SCHMIDT B, Soerensen SJC, Bhambhvani HP, Fan RE, et al
     External validation of an artificial intelligence model for Gleason grading of prostate cancer on prostatectomy specimens.
     BJU Int. 2024 Jul 11. doi: 10.1111/bju.16464.
     PubMed     Abstract available
     
     
     
171. WENZEL M, Hoeh B, Koll F, Humke C, et al
     Impact of homologous recombination repair/BReast CAncer (BRCA) gene alterations on survival in a real-world setting of metastatic prostate cancer.
     BJU Int. 2024 Jul 10. doi: 10.1111/bju.16462.
     PubMed     Abstract available
     
     
     
172. ARVIDSSON I, Svanemur E, Marginean F, Simoulis A, et al
     Artificial intelligence for detection of prostate cancer in biopsies during active surveillance.
     BJU Int. 2024 Jul 4. doi: 10.1111/bju.16456.
     PubMed     Abstract available
     
     
     
173. 
     Pembrolizumab for the treatment of bladder and renal cancer and important new data concerning screening for prostate cancer.
     BJU Int. 2024;134:4-5.
     PubMed    
     
     
     
174. JUSSILA I, Ahtiainen JP, Laakkonen EK, Siltari A, et al
     Transdermal oestradiol and exercise in androgen deprivation therapy (ESTRACISE): protocol.
     BJU Int. 2024;134:110-118.
     PubMed     Abstract available
     
     
     
175. SOPUTRO NA, Chavali JS, Ferguson EL, Ramos-Carpinteyro R, et al
     Complications of single-port robot-assisted radical prostatectomy: multi-institutional analysis from the Single-Port Advanced Research Consortium (SPARC).
     BJU Int. 2024;134:54-62.
     PubMed     Abstract available
     
     
     
176. MORETTI TBC, Magna LA, Reis LO
     Continence criteria of 193 618 patients after open, laparoscopic, and robot-assisted radical prostatectomy.
     BJU Int. 2024;134:13-21.
     PubMed     Abstract available
     
     
     June 2024
177. KATO T, Matsumoto R, Yokomizo A, Tohi Y, et al
     Outcomes of active surveillance for Japanese patients with prostate cancer (PRIAS-JAPAN).
     BJU Int. 2024 Jun 17. doi: 10.1111/bju.16436.
     PubMed     Abstract available
     
     
     
178. BANCROFT EK, Page EC, Brook MN, Pope J, et al
     The psychosocial impact of prostate cancer screening for BRCA1 and BRCA2 carriers.
     BJU Int. 2024 Jun 5. doi: 10.1111/bju.16432.
     PubMed     Abstract available
     
     
     
179. HAHN AW, Manyam GC, Chapin BF, Zhang M, et al
     A phase II trial of apalutamide for intermediate-risk prostate cancer and molecular correlates.
     BJU Int. 2024 Jun 4. doi: 10.1111/bju.16414.
     PubMed     Abstract available
     
     
     
180. 
     Prostate cancer: To screen, or not to screen? That is the question.
     BJU Int. 2024;133:635-637.
     PubMed    
     
     
     
181. FRANCO A, Ditonno F, Manfredi C, Licari LC, et al
     Robot-assisted single-port transvesical enucleation of the prostate: step-by-step technique and early single-centre experience.
     BJU Int. 2024;133:778-782.
     PubMed    
     
     
     
182. NOLSOE AB, Ostergren PB, Jakobsen H, Jensen CFS, et al
     Can nerve monitoring during radical prostatectomy improve functional outcomes? A randomised trial.
     BJU Int. 2024;133:742-751.
     PubMed     Abstract available
     
     
     
183. MAURER J, Friedemann T, Chen Y, Ambrosini F, et al
     A randomized controlled study on acupuncture for peri-operative pain after open radical prostatectomy.
     BJU Int. 2024;133:725-732.
     PubMed     Abstract available
     
     
     
184. LENFANT L, Beitone C, Troccaz J, Roupret M, et al
     Learning curve for fusion magnetic resonance imaging targeted prostate biopsy and three-dimensional transrectal ultrasonography segmentation.
     BJU Int. 2024;133:709-716.
     PubMed     Abstract available
     
     
     
185. ALMEIDA-MAGANA R, Au M, Al-Hammouri T, Dinneen K, et al
     Improving fluorescence confocal microscopy for margin assessment during robot-assisted radical prostatectomy: The LaserSAFE technique.
     BJU Int. 2024;133:677-679.
     PubMed    
     
     
     
186. MAC CURTAIN BM, Sugrue DD, Qian W, O'Callaghan M, et al
     Membranous urethral length and urinary incontinence following robot-assisted radical prostatectomy: a systematic review and meta-analysis.
     BJU Int. 2024;133:646-655.
     PubMed     Abstract available
     
     
     May 2024
187. GALIETTA E, Strolin S, Lodi-Rizzini E, Castellucci P, et al
     Case of the month from the Radiotherapy Unit, Department of Medical and Surgical Sciences, University of Bologna, Italy: breaking boundaries beyond five lesions with multifocal stereotactic radiotherapy in prostate cancer.
     BJU Int. 2024 May 22. doi: 10.1111/bju.16399.
     PubMed    
     
     
     
188. PELTIER A, van Velthoven R, Baudewyns A, Assenmacher G, et al
     Targeted microwave ablation for prostate cancer (FOSTINE1b): a prospective 'ablate-and-resect' study.
     BJU Int. 2024 May 14. doi: 10.1111/bju.16385.
     PubMed     Abstract available
     
     
     
189. BENJAMIN DJ, Yazdanpanah O, Rezazadeh Kalebasty A
     A review of vitamin use for the prevention or treatment of prostate cancer.
     BJU Int. 2024 May 13. doi: 10.1111/bju.16398.
     PubMed    
     
     
     
190. PASANEN N, Talala K, Remmers S, Tammela TLJ, et al
     Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer.
     BJU Int. 2024 May 9. doi: 10.1111/bju.16394.
     PubMed     Abstract available
     
     
     
191. GRAJALES V, Martini A, Shore ND
     Complications of immuno-oncology care: what urologist should know.
     BJU Int. 2024;133:524-531.
     PubMed     Abstract available
     
     
     
192. CHALOUPKA M, Pyrgidis N, Ebner B, Volz Y, et al
     Added value of randomised biopsy to multiparametric magnetic resonance imaging-targeted biopsy of the prostate in a contemporary cohort.
     BJU Int. 2024;133:548-554.
     PubMed     Abstract available
     
     
     April 2024
193. SIMHAL RK, Wang KR, Shah YB, Lallas CD, et al
     Peri-operative outcomes following radical prostatectomy in the setting of advanced prostate cancer.
     BJU Int. 2024 Apr 23. doi: 10.1111/bju.16370.
     PubMed     Abstract available
     
     
     
194. STATTIN P, Fleming S, Lin X, Lefresne F, et al
     Population-based study of disease trajectory after radical treatment for high-risk prostate cancer.
     BJU Int. 2024 Apr 15. doi: 10.1111/bju.16362.
     PubMed     Abstract available
     
     
     
195. RODRIGUEZ-SANCHEZ L, Reiter R, Rodriguez A, Emberton M, et al
     The FocAL therapy CONsensus (FALCON): enhancing partial gland ablation for localised prostate cancer.
     BJU Int. 2024 Apr 13. doi: 10.1111/bju.16360.
     PubMed    
     
     
     
196. BERRIDGE C, Omer A, Lopez F, Bryant RJ, et al
     Perspectives on technology - prostate cancer: is local anaesthetic transperineal prostate biopsy really better than transrectal biopsy?
     BJU Int. 2024 Apr 8. doi: 10.1111/bju.16349.
     PubMed     Abstract available
     
     
     
197. VICKERS A
     Magnetic resonance imaging-targeted prostate biopsy changed everything (so everything has to change).
     BJU Int. 2024;133:354-355.
     PubMed    
     
     
     
198. MCNICHOLAS DP, Parr NJ
     Image intensifier-guided transperineal prostate biopsy for patients without a rectum: novel technique.
     BJU Int. 2024;133:487-490.
     PubMed     Abstract available
     
     
     
199. JABBOUR T, Peltier A, Rocq L, Sirtaine N, et al
     Magnetic resonance imaging targeted biopsy in biopsy-naive patients and the risk of overtreatment in prostate cancer: a grading issue.
     BJU Int. 2024;133:432-441.
     PubMed     Abstract available
     
     
     
200. MEHAWED G, Murray R, Rukin NJ, Roberts MJ, et al
     Prostate tumour visualisation with PET: is image fusion with MRI the answer?
     BJU Int. 2024;133 Suppl 4:4-6.
     PubMed    
     
     
     March 2024
201. ALBERTSEN PC
     Response to 'Endpoint and control group in prostate cancer screening research: public health basics'.
     BJU Int. 2024 Mar 30. doi: 10.1111/bju.16357.
     PubMed    
     
     
     
202. TAKAHASHI T
     Endpoint and control group in prostate cancer screening research: public health basics.
     BJU Int. 2024 Mar 29. doi: 10.1111/bju.16356.
     PubMed    
     
     
     
203. PAK JS, Huang R, Huang WC, Lepor H, et al
     Interaction of patient age and high-grade prostate cancer on targeted biopsies of MRI suspicious lesions.
     BJU Int. 2024 Mar 27. doi: 10.1111/bju.16341.
     PubMed     Abstract available
     
     
     
204. PARRY MG, Sujenthiran A, Nossiter J, Morris M, et al
     Reply to: Letter to the editor regarding the article 'Prostate cancer outcomes following whole-gland and focal high-intensity focused ultrasound'.
     BJU Int. 2024 Mar 22. doi: 10.1111/bju.16348.
     PubMed    
     
     
     
205. HAMDY FC, Albertsen PC, Donovan JL
     Screening and active surveillance in prostate cancer: the dilemma continues.
     BJU Int. 2024 Mar 21. doi: 10.1111/bju.16345.
     PubMed    
     
     
     
206. HUBER J, Karschuck P, Valdix J, Thomas C, et al
     Online decision aid for patients with prostate cancer evaluated by 11 290 patients and 91 urologists in Germany.
     BJU Int. 2024 Mar 20. doi: 10.1111/bju.16329.
     PubMed     Abstract available
     
     
     
207. TAKAHASHI T
     Active surveillance in all cases of screen-detected prostate cancer.
     BJU Int. 2024 Mar 20. doi: 10.1111/bju.16344.
     PubMed    
     
     
     
208. ROKAN N, Reddy D, Dudderidge T
     Focal therapy for prostate cancer - when to refer?
     BJU Int. 2024 Mar 13. doi: 10.1111/bju.16315.
     PubMed    
     
     
     
209. VAN HARTEN MJ, Roobol MJ, van Leeuwen PJ, Willemse PM, et al
     Evolution of European prostate cancer screening protocols and summary of ongoing trials.
     BJU Int. 2024 Mar 12. doi: 10.1111/bju.16311.
     PubMed     Abstract available
     
     
     
210. LOFFELER S, Bertilsson H, Muller C, Aas K, et al
     Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged >/=75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P).
     BJU Int. 2024 Mar 12. doi: 10.1111/bju.16314.
     PubMed     Abstract available
     
     
     
211. HONORE A, Moen CA, Juliebo-Jones P, Reisaeter LAR, et al
     Transitioning from transrectal to transperineal prostate biopsy using a freehand cognitive approach.
     BJU Int. 2024;133:324-331.
     PubMed     Abstract available
     
     
     February 2024
212. GEBOERS B, Scheltema MJV, Emmett L, Stricker PD, et al
     Reply to 'Re: Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy'.
     BJU Int. 2024 Feb 28. doi: 10.1111/bju.16308.
     PubMed    
     
     
     
213. LEMANSKA A, Andrews C, Fisher L, Bacon S, et al
     During the COVID-19 pandemic 20 000 prostate cancer diagnoses were missed in England.
     BJU Int. 2024 Feb 27. doi: 10.1111/bju.16305.
     PubMed     Abstract available
     
     
     
214. ZUUR LG, de Barros HA, van Oosterom MN, Berrens AC, et al
     (99m) TcPSMA-radioguided surgery in oligorecurrent prostate cancer: the randomised TRACE-II trial.
     BJU Int. 2024 Feb 12. doi: 10.1111/bju.16297.
     PubMed     Abstract available
     
     
     
215. DE MARIA M, Meneghetti I, Mosillo L, Collins JW, et al
     Versius robotic surgical system: case series of 18 robot-assisted radical prostatectomies.
     BJU Int. 2024;133:197-205.
     PubMed     Abstract available
     
     
     
216. DEARNALEY D, Griffin CL, Silva P, Wilkins A, et al
     International Society of Urological Pathology (ISUP) Gleason Grade Groups stratify outcomes in the CHHiP Phase 3 prostate radiotherapy trial.
     BJU Int. 2024;133:179-187.
     PubMed     Abstract available
     
     
     
217. PTASZNIK G, Kelly BD, Murphy D, Lawrentschuk N, et al
     How prostate-specific membrane antigen positron emission tomography is refining risk calculators in the primary prostate diagnostic pathway.
     BJU Int. 2024;133 Suppl 3:13-14.
     PubMed    
     
     
     
218. ROBERTS MJ, Conduit C, Davis ID, Effeney RM, et al
     The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.
     BJU Int. 2024;133 Suppl 3:39-47.
     PubMed     Abstract available
     
     
     January 2024
219. SANCHEZ-SALAS R
     Candid choices: optimising patient selection in prostate cancer focal therapy.
     BJU Int. 2024 Jan 20. doi: 10.1111/bju.16270.
     PubMed    
     
     
     
220. BESIROGLU H
     Re: 'Prostate cancer outcomes following whole-gland and focal high-intensity focused ultrasound'.
     BJU Int. 2024 Jan 18. doi: 10.1111/bju.16277.
     PubMed    
     
     
     
221. TALWAR R, Akinsola O, Penson DF
     What is cancer? A focus on Grade Group 1 prostate cancer.
     BJU Int. 2024 Jan 16. doi: 10.1111/bju.16280.
     PubMed     Abstract available
     
     
     
222. ALBERTSEN PC, Bjerner LJ, Pasovic L, Muller S, et al
     Opportunistic prostate-specific antigen testing in Norwegian men: a public health challenge.
     BJU Int. 2024;133:104-111.
     PubMed     Abstract available
     
     
     
223. MAYOR N, Eldred-Evans D, Tam H, Sokhi H, et al
     Prostagram magnetic resonance imaging in a screening population: Prostate Imaging-Reporting and Data System or Likert?
     BJU Int. 2024;133:112-117.
     PubMed     Abstract available
     
     
     December 2023
224. GUERCIO A, Franco G, Lombardo R, De Nunzio C, et al
     LETTER TO THE EDITOR Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy.
     BJU Int. 2023 Dec 14. doi: 10.1111/bju.16263.
     PubMed    
     
     
     
225. LENI R, Roscigno M, Barzaghi P, La Croce G, et al
     Medium-term follow up of active surveillance for early prostate cancer at a non-academic institution.
     BJU Int. 2023 Dec 14. doi: 10.1111/bju.16259.
     PubMed     Abstract available
     
     
     November 2023
226. GABRIEL J, Gabriel A, Shafik L, Alanbuki A, et al
     AI in the urology MDM: can ChatGPT suggest EAU guideline-recommended prostate cancer treatments?
     BJU Int. 2023 Nov 27. doi: 10.1111/bju.16240.
     PubMed    
     
     
     
227. SHANMUGASUNDARAM R, Saad J, Heyworth A, Wong V, et al
     Intra-individual comparison of prostate-specific membrane antigen positron emission tomography/computed tomography versus bone scan in detecting skeletal metastasis at prostate cancer diagnosis.
     BJU Int. 2023 Nov 9. doi: 10.1111/bju.16115.
     PubMed     Abstract available
     
     
     
228. PARRY MG, Sujenthiran A, Nossiter J, Morris M, et al
     Prostate cancer outcomes following whole-gland and focal high-intensity focused ultrasound.
     BJU Int. 2023;132:568-574.
     PubMed     Abstract available
     
     
     
229. HAAPIAINEN H, Murtola TJ, Koskimaki J, Riikonen J, et al
     Robot-assisted versus three-dimensional laparoscopic radical prostatectomy: 12-month outcomes of a randomised controlled trial.
     BJU Int. 2023;132:505-511.
     PubMed     Abstract available
     
     
     
230. CUSSENOT O, Cancel-Tassin G, Rao SR, Woodcock DJ, et al
     Aligning germline and somatic mutations in prostate cancer. Are genetics changing practice?
     BJU Int. 2023;132:472-484.
     PubMed     Abstract available
     
     
     
231. ALHUSSEINAWI H, Sander L, Rosenvinge PM, Jensen SL, et al
     Low- versus standard- pneumoperitoneum in patients undergoing robot-assisted radical prostatectomy: a randomised, triple-blinded study.
     BJU Int. 2023;132:560-567.
     PubMed     Abstract available
     
     
     October 2023
232. BAGGULEY D, Harewood L, McKenzie D, Ptasznik G, et al
     CONFIRM trial Protocol: The utility of PSMA PET/CT in active surveillance for prostate cancer.
     BJU Int. 2023 Oct 30. doi: 10.1111/bju.16214.
     PubMed     Abstract available
     
     
     
233. KAUFMANN B, Raess E, Schmid FA, Bieri U, et al
     Focal Therapy with High-Intensity Focused Ultrasound for Prostate Cancer: Three Year Outcomes from a Prospective Trial.
     BJU Int. 2023 Oct 27. doi: 10.1111/bju.16213.
     PubMed     Abstract available
     
     
     
234. GEBOERS B, Meijer D, Counter W, Blazevski A, et al
     PSMA-PET in Addition to mpMRI and Biopsies to Select Prostate Cancer Patients for Focal Therapy.
     BJU Int. 2023 Oct 19. doi: 10.1111/bju.16207.
     PubMed     Abstract available
     
     
     
235. TISSOT S, Wynn J, Tran V, Farag M, et al
     Re-defining (18) F-DCFPyl prostate-specific membrane antigen positron emission tomography detected local recurrence from radical prostatectomy histopathology.
     BJU Int. 2023;132:411-419.
     PubMed     Abstract available
     
     
     
236. BOEVE LMS, Bloemendal FT, de Bie KCC, van Haarst EP, et al
     Cancer detection and complications of transperineal prostate biopsy with antibiotics when indicated.
     BJU Int. 2023;132:397-403.
     PubMed     Abstract available
     
     
     September 2023
237. LEHNER F, Crippa A, Sigg S, Eberli D, et al
     Transperineal template saturation and conventional biopsy for stage prediction in prostate cancer.
     BJU Int. 2023 Sep 13. doi: 10.1111/bju.16181.
     PubMed     Abstract available
     
     
     
238. JALLOH M, Cassell A, Niang L, Rebbeck T, et al
     Global Viewpoints: Updates on Prostate cancer in Sub-Saharan Africa.
     BJU Int. 2023 Sep 13. doi: 10.1111/bju.16178.
     PubMed     Abstract available
     
     
     
239. PATTENDEN TA, Thangasamy IA, Ong WL, Samaranayke D, et al
     Barriers and enablers of active surveillance for prostate cancer - a qualitive study of clinicians.
     BJU Int. 2023 Sep 11. doi: 10.1111/bju.16176.
     PubMed     Abstract available
     
     
     June 2023
240. BRANT A, Campi R, Carrion DM, Esperto F, et al
     Findings from an international survey of urology trainee experience with prostate biopsy.
     BJU Int. 2023;131:705-711.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum